Abstract The continued evolution of SARS-CoV-2 variants that evade immunity highlights a need to develop vaccines that elicit variant-specific antibodies and neutralize emerging strains. However, immune imprinting from antecedent SARS-CoV-2 exposure can limit the generation of such antibodies.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Suzanne M. Scheaffer
Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain
Abstract Boosting with mRNA vaccines encoding variant-matched spike proteins has been implemented to mitigate their reduced efficacy against emerging SARS-CoV-2 variants. Nonetheless, in humans, it remains unclear whether boosting in the ipsilateral or contralateral arm with respect to the priming doses impacts immunity and protection.
NVX-CoV2373 ancestral and NVX-CoV2540 BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters
Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.
Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron Variants in Mice and Hamsters
Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant
New Results doi: https://doi.org/10.1101/2022.09.12.507614 ABSTRACT The emergence of SARS-CoV-2 variants in the Omicron lineage with large numbers of substitutions in the spike protein that can evade antibody neutralization has resulted in diminished vaccine efficacy and persistent transmission. One strategy to broaden vaccine-induced immunity is to administer bivalent vaccines that encode for spike proteins from both historical and newly-emerged variant strains.
Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice
HIGHLIGHTS • Primary immunization series with mRNA-1273 results in BA.1 breakthrough infection • Primary immunization with BA.1-matched vaccine neutralizes BA.1 but not Wuhan-1 • Both mRNA-1273 and BA.1-matched boosters protect against BA.1 challenge • A BA.1-matched booster induces greater neutralizing antibody responses against BA.1 SUMMARY The large number of spike substitutions in Omicron lineage variants (BA.1, BA.1.1. and BA.2) could jeopardize the efficacy of SARS-CoV-2 vaccines.
Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice
New Results Baoling Ying, Suzanne M. Scheaffer, Bradley Whitener, Chieh-Yu Liang, Oleksandr Dmytrenko, Samantha Mackin, Kai Wu, Diana Lee, Laura E. Avena, Zhenlu Chong, James Brett Case, LingZhi Ma, Thu Kim, Caralyn Sein, Angela Woods, Daniela Montes Berrueta, Andrea Carfi, Sayda M. Elbashir, Darin K. Edwards, Larissa B. Thackray, View ORCID ProfileMichael S.
Author Correction: Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection
Correction to: Nature Immunology https://www.nature.com/articles/ni.3849, published online 25 September 2017. In the version of this article originally published, the label (‘Infection (%)’) along the vertical axis of each plot in Fig. 1d was incorrect. The correct label is ‘Neutralization (%)’.
Interferon lambda protects the female reproductive tract against Zika virus infection
Abstract Although Zika virus (ZIKV) can be transmitted sexually and cause congenital birth defects, immune control mechanisms in the female reproductive tract (FRT) are not well characterized. Here we show that treatment of primary human vaginal and cervical epithelial cells with interferon (IFN)-α/β or IFN-λ induces host defense transcriptional signatures and inhibits ZIKV infection.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Suzanne M.
Contact Suzanne M., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack